Idiopathic pulmonary fibrosis (IPF) is a progressive fibroproliferative disease whose molecular pathogenesis remains unclear. In a recent paper, we demonstrated a key role for the PI3K pathway in both proliferation and differentiation into myofibroblasts of normal human lung fibroblasts treated with TGF-b. In this research, we assessed the expression of class I PI3K p110 isoforms in IPF lung tissue as well as in tissue-derived fibroblast cell lines. Moreover, we investigated the in vitro effects of the selective inhibition of p110 isoforms on IPF fibroblast proliferation and fibrogenic activity. IHC was performed on normal and IPF lung tissue. Expression levels of PI3K p110 isoforms were evaluated by western blot and flow cytometry analysis. Fibroblast cell lines were established from both normal and IPF tissue and the effects of selective pharmacological inhibition as well as specific gene silencing by small interfering RNAs were studied in vitro. No significant differences between normal and IPF tissue/tissue-derived fibroblasts were observed for the expression of PI3K p110 a, b and d isoforms whereas p110g was more greatly expressed in both IPF lung homogenates and ex vivo fibroblast cell lines. Myofibroblasts and bronchiolar basal cells in IPF lungs exhibited strong immunoreactivity for p110g. Positive staining for the markers of proliferation proliferating cell nuclear antigen and cyclin D1 was also shown in cells of fibrolastic foci. Furthermore, both p110g pharmacological inhibition and gene silencing were able to significantly inhibit proliferation rate as well as a-SMA expression in IPF fibroblasts. Our data suggest that PI3K p110g isoform may have an important role in the etio-pathology of IPF and can be a specific pharmacological target. Idiopathic pulmonary fibrosis (IPF) is a relentless interstitial lung disease characterized by fibroblast/myofibroblast accumulation in the alveolar wall and aberrant matrix deposition leading to distortion of the alveolar architecture and the consequent loss of respiratory function. 1 The typical IPF morphological lesion is the fibroblastic focus, in which fibroblasts/myofibrolasts are embedded in a type I collagenrich matrix. It has been theorized that IPF fibroblasts hold intrinsic alterations of key components of their cellular machinery yet molecular mechanisms differentiating IPF fibroblasts from their normal counterparts remain unknown. In a recent paper, we pinpointed a key role for the PI3K pathway in both proliferation and differentiation into myofibroblasts of lung fibroblasts treated with TGF-b. 2 PI3K signaling has been implicated in a variety of cellular activities including proliferation, survival, adhesion, differentiation, cytoskeletal organization, and so on. 3, 4 The various PI3Ks discovered have been divided into three classes according to their structure and lipid substrate specificity. The most extensively investigated are the class I PI3Ks which, in response to the activation of receptor tyrosine kinases, G protein coupled receptors/cytokine receptors and activated Ras, catalyze the phosphorylation of phosphatidylinositol (4,5)-biphosphate (PIP2) to form phosphatidylinositol (3,4,5)-triphosphate (PIP3). Prototypical class I PI3K is a dimeric enzyme, consisting of a regulatory and catalytic subunit. The latter
Idiopathic pulmonary fibrosis (IPF) is a relentless interstitial lung disease characterized by fibroblast/myofibroblast accumulation in the alveolar wall and aberrant matrix deposition leading to distortion of the alveolar architecture and the consequent loss of respiratory function. 1 The typical IPF morphological lesion is the fibroblastic focus, in which fibroblasts/myofibrolasts are embedded in a type I collagenrich matrix. It has been theorized that IPF fibroblasts hold intrinsic alterations of key components of their cellular machinery yet molecular mechanisms differentiating IPF fibroblasts from their normal counterparts remain unknown. In a recent paper, we pinpointed a key role for the PI3K pathway in both proliferation and differentiation into myofibroblasts of lung fibroblasts treated with TGF-b. 2 PI3K signaling has been implicated in a variety of cellular activities including proliferation, survival, adhesion, differentiation, cytoskeletal organization, and so on. 3, 4 The various PI3Ks discovered have been divided into three classes according to their structure and lipid substrate specificity. The most extensively investigated are the class I PI3Ks which, in response to the activation of receptor tyrosine kinases, G protein coupled receptors/cytokine receptors and activated Ras, catalyze the phosphorylation of phosphatidylinositol (4,5)-biphosphate (PIP2) to form phosphatidylinositol (3,4,5)-triphosphate (PIP3). Prototypical class I PI3K is a dimeric enzyme, consisting of a regulatory and catalytic subunit. The latter occurs in four isoforms, designated p110a, p110b, p110g and p110d, which are subgrouped into class IA (p110a, p110b and p110d) and IB (p110g). By utilizing pharmacological inhibitors as well as genetic manipulation distinct roles for individual PI3K isoforms have been revealed and distinct kinase functions as well as kinase-independent functions demonstrated. 5 Although little is currently known about the role of the specific isoforms in airway diseases, targeting specific PI3K isoforms that may be overexpressed or overactive in disease should provide for effective therapeutic treatments. For instance, emerging data from animal models, primary cells and clinical studies in other diseases suggest that specific PI3K/Akt inhibitors can be therapeutically utilized in the treatment of asthma and chronic obstructive pulmonary disease. [6] [7] [8] In this research, we investigated the expression of the class I PI3K isoforms in IPF lung tissue and tissue-derived fibroblasts as well in normal controls. Moreover, ex vivo fibroblast cell lines were used to investigate the effects of isoform-selective inhibitors as well as of specific small interfering RNAs (siRNAs) in fibroblast proliferation and fibrogenic activity.
MATERIALS AND METHODS Lung Tissues
We utilized IPF tissues from patients with IPF (n ¼ 31, mean age 49±11 years; 13 woman, 17 men; in one case, age and gender were unknown) and controls (n ¼ 15, mean age 47 ± 17 years; 5 women, 8 men; in two cases, age and gender were unknown) from unused organ donors or histologically normal areas of biopsies from surgical operations. Retrospectively, the diagnosis of IPF was reviewed and validated (L Fink, A Guenther) using current American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines, 9 and patients were included only when current ATS/ERS criteria were met. The study protocol was approved by the ethics committee of the Justus-Liebig-University School of Medicine (no. 31/93, 84/93, 29/01). Informed consent was obtained in written form from each subject for the study protocol.
Lung homogenates were prepared conventionally.
Cell Cultures
Lung fibroblast cells were derived from IPF lungs (retrospectively diagnosed as above specified) or histologically normal areas of surgical lung specimens from patients undergoing resective surgery. Primary lines were established by using an outgrowth from explants according to the method by Jordana et al 10 as previously described. 11 In all the experiments, cell lines were used at a passage earlier than the eight. Before treatment, cells were plated and incubated for 24 h in serum-free RPMI medium. Afterward, cells were grown for 48 h in 2% FBS medium in the absence or presence of PI3K inhibitors. Proliferation rate, AKT phosphorilation, a-SMA and collagen production were then evaluated.
Transfections with commercially available siRNAs specific for PI3K p110g as well as with a negative control (Qiagen, Flexi Tube Gene Solution SI00605843, SI02665369 and AllStars Negative Control, respectively) were performed by using Hiperfect Transfection Reagent (Qiagen, Milan, Italy) following the manufacturer's protocol.
PI3K Inhibitors
Ly294002, AS-252424, TGX-221 and IC87114 were commercially available, YM-024 was kindly provided by Professor Shaun P Jackson (Australian Center for Blood Diseases, Monash University, Melbourne, Australia). TGF-b was from Chemicon. All other reagents were from Sigma.
Cell Proliferation
Cell numbers were determined by counting cells in triplicate on a hemocytometer (Burker chamber) after Trypan blue staining at time 0 (before serum starvation) and after treatments. A mean of four fields was used to calculate the average number of cells. PI3K p110c overexpression in IPF lung tissue E Conte et al
Collagen Production
Total soluble collagen was measured by the Sircol Soluble Collagen Assay (Biocolor, Newtownabbey, UK). The collagen-dye complex was precipitated by centrifugation at 10 000 Â g for 10 min. The precipitated complex was resuspended in 1 ml alkali reagent. The solution obtained was Figure 2 (Continued on next page). 
Western Blot Analysis
Lung homogenates or cell lysates were subjected to denaturating SDS gel electrophoresis followed by electroblotting and incubation with monoclonal mouse anti-human a-SMA Ab (1:1000, Dako Cytomation, Denmark), or rabbit anti-human pospho(Ser 473 )-Akt (1:500; Cell Signaling Technology, Beverly, MA, USA), monoclonal rabbit anti-human PI3Kp110a (1:500, Cell Signaling Technology), monoclonal rabbit anti-human PI3Kp110b (1:500, Abcam), monoclonal mouse anti-human PI3Kp110g (1:500, Abcam), monoclonal rabbit anti-human PI3Kp110d (1:500, Abcam) and monoclonal mouse antihuman GAPDH (1:1000, Millipore, Milan, Italy). The membranes were then thoroughly washed and incubated with biotinconjugated anti-mouse or anti-rabbit secondary antibodies (1:5000; Life Technologies) and developed with the Quantum Dot detection system (Invitrogen). The band intensity of exposed film was analyzed by densitometric scanning and quantified using the Image J (NIH, free share) software. Immunocytochemistry After reaching 80%, confluence cells were first washed with PBS, then fixed with 4% paraformaldheyde in PBS for 30 min and incubated for 30 min with a 5% solution of normal goat serum (Sigma-Aldrich). They were subsequently incubated overnight at 4 1C with the PI3K p110g primary antibody mentioned above (1:100 dilution). After washing, cells were incubated at room temperature with Cy3-conjugated goat anti-rabbit secondary antibody. Afterward cell were incubated with 4 0 -6-diamidino-2-phenylindole (DAPI, Life Technologies 1:10 000) for nuclear staining, 10 min in the dark and then washed once. As a control, the specificity of immunostaining was verified by omitting incubation with the primary or secondary antibody. Digital images were acquired using a Leica DMRB fluorescence microscope (Leica Microsystems Srl, Milan, Italy) equipped with a computer-assisted Nikon digital camera (Nital SpA, Turin, Italy). Moreover, basal cell sheets, as indicated in serial sections by nuclear p63 and cytoplasmic KRT5 staining (dashed arrows in c and d, respectively), were also positive for p110g (dashed arrows in a). In the overlying epithelium of this area, no type II alveolar epithelial cells (AECIIs) were observed as proven by the absence of proSP-C staining (e). In general, the type-II alveolar epithelial cells (AECIIs) of IPF lungs (stained by proSP-C and indicated by arrows in g) revealed none or no notable immunoreactivity for p110g antibodies (arrows in i). p110g-positive basal cell layers were also often observed in areas of bronchiolization including abnormalities such as squamous metaplasia (i) or hyperplastic bronchioles (j). In addition, luminal bronchiolar cells in IPF lungs (ciliated and non-ciliated) also expressed p110g (a, j). In control lungs, a basal, normal level of p110g expression was observed in luminal bronchiolar cells, whereas the basal cells of normal bronchioles reveal no notable immunoreactivity (l, m). Similarly, AECII of control lungs revealed none or faint immunoreactivity to p110g (k, l). Finally, in both IPF-and control lungs pronounced nuclear staining for p110g was also observed in interstitial inflammatory cells (i, j, l). Original magnification of photomicrographs (a-f) (left), and (j): Â 200 (bar ¼ 100 mm); original magnification of photomicrographs (a-f) (right), and (g-j, k-m): Â 400 (bar ¼ 50 mm). FF, fibroblast foci; Neg. control, negative control.
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Immunoreactivity was evaluated taking into account the signal-to-noise ratio of immunofluorescence.
Statistical Analysis
Statistical significance across treatment groups was determined by one-way ANOVA with Tukey's multiple-comparison with Statgraphic Centurion XV software (StatPoint Technologies Inc., Adalta, Italy). A P-value o0.05, which indicates a statistically significant difference, is designated with a single asterisk.
RESULTS

PI3K p110c is Overexpressed in IPF Lung Tissues
Tissues from patients with IPF (n ¼ 31) and controls from organ donors or histologically normal areas of biopsies from surgical operations (n ¼ 15) were utilized for western blot analysis of PI3K p110 isoforms' expression. We observed no significant differences between IPF and control tissues in p110a, p110b and p110d expression (data not shown) whereas p110g appeared overexpressed in IPF lung tissue, as shown in Figure 1 . Densitometric quantification of normalized immunoblots revealed an approximate median 1.5-fold increase in p110g content in IPF tissue compared with controls (Po0.05).
Based on this evidence, immunohistochemical analysis for p110g was performed on serial paraffin-embedded tissue sections of IPF and control lungs. Figure 2 ) revealed pronounced nuclear expression of PI3K p110g, which was only barely detectable in the basal portion of normal lung tissues (Figures 2l and m) and also in normal bronchioles of IPF lungs (which in some areas have unaffected lung tissue, data not shown). In addition, luminal bronchiolar cells (ciliated and non-ciliated) in IPF lungs revealed also robust nuclear expression of p110g (Figures 2a and j) , whereas only basal expression was observed in bronchioles of donor lung tissues (Figure 2l ). As expected, in both categories some interstitial inflammatory 
PI3K p110c is Overexpressed in Fibroblasts Derived from IPF Lung Tissues
Western blot and flow cytometry analysis was performed for PI3K p110 isoforms in fibroblast cell lines established from both normal and IPF tissues. Paralleling data obtained from tissue observations, no significant differences between normal and IPF fibroblasts were noted for the expression of p110a, b and d (data not shown) whereas p110g was significantly overexpressed in IPF fibroblasts, as evidenced by western blot analysis (Figures 3a and b) and flow cytometry (Figure 3c ). Immunocytochemical analysis revealed the nuclear localization of p110g (Figure 3d ).
Effects of Pharmacological Inhibition of Class I PI3K p110 Isoforms in Ex Vivo Normal and IPF Fibroblasts
Cells were grown for 48 h in 2% FBS medium in the absence or presence of PI3K inhibitors, after initially 24 h in serumfree medium. Selective inhibitors of class I PI3K isoforms (YM-024, TGX-221 and IC87114 for class IA p110a, p110b and p110d, respectively; AS-252424 for class IB p110g) and the PI3K pan-inhibitor Ly294002 as control were used to evaluate any effects on fibrotic activity and cell proliferation of IPF fibroblasts in comparison with normal cells. As shown in Figures 4a and b , significant inhibition of AKT phosphorylation and a-SMA expression was achieved in IPF fibroblasts by the p110g inhibitor AS252424, although only at the highest dose, and as expected by the pan inhibitor Ly294002, whereas collagen content in supernatants was unaffected by all inhibitors of the PI3K p110 isoforms, as shown in panel 4c. At variance with this finding, the p110g inhibitor AS252424 did significantly inhibit cell proliferation in IPF fibroblasts, yet did not in normal fibroblasts where significant proliferation impairment was observed by inhibiting p110a activity with YM-024 treatment, as shown in Figure 4d .
Effects of the Selective Gene Targeting of p110c in Normal and IPF Fibroblasts
In addition to pharmacological inhibition, specific PI3K p110g gene silencing was performed by transfection of cells with siRNAs specifically targeting p110g RNAs. siRNAs with no homology to any known mammalian gene served as a negative controls. Selectivity of p110g siRNAs was checked by immunoblotting with antibodies against all four p110 Figure 3) . At variance with our previous research, 2 in this study we used lower concentrations of siRNAs (1-5 nmol, compared with previous 20-50 nmol) although with a more efficient carrier. In Figures 5  and 6 are shown data from at least three separate transfections in three different cell lines of both IPF and normal fibroblasts (unstimulated or stimulated with TGF-b), which obtained comparable results. As indicated by the representative western blots and pertinent densitometric analysis of the overall data relative to both unstimulated and TGF-bstimulated cells (Figures 5a and b, respectively) , IPF fibroblast transfections with siRNAs targeting p110g gene expression produced a significant inhibition of AKT-Ser473 phosphorylation compared with the negative controls. The expression of a-SMA also was significantly inhibited compared with the untransfected cells but we observed an offtarget effect of the negative control siRNA that significantly inhibited a-SMA expression yet leaving AKT-Ser473 phosphorylation unaffected. We thus investigated this off-target effect by using other unrelated negative control siRNAs and we observed the same inhibitory effect (limited to the a-SMA expression only). Further experiments are needed to explain this unexpected finding. It is noteworthy that specific p110g gene targeting significantly inhibited cell proliferation in unstimulated IPF fibroblasts whereas did not in normal fibroblasts, at least at low siRNA concentrations that were used in these experiments (Figure 6a) . Moreover, transfections of IPF fibroblasts with siRNAs targeting p110g were able to significantly inhibit cell proliferation also in the presence of TGF-b (Figure 6b) .
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Paralleling data obtained with the pharmacological inhibition, collagen content in supernatants of unstimulated IPF fibroblasts were not affected by specific p110g gene targeting, as shown in Table 1 . Differently, the increase in collagen release induced by TGF-b was significantly inhibited by p110g gene targeting.
Fibroblastic Cells in IPF Lung Tissues Express Markers of Proliferation PCNA and Cyclin D1
The results obtained from in vitro studies of fibroblasts prompted us to re-analyze the IPF lung tissues in order to consider a putative in situ proliferation activity of fibroblastic cells. A previous study 13 reported that spindle-shaped cells within fibroblastic foci are positive for PCNA, yet PCNA specificity as marker of proliferation was subsequently questioned. 14 Therefore, besides PCNA, in this study we evaluated the expression of cyclin D1, a factor strictly required for progression through the G1 phase in the cell cycle.
As shown by results of IHC on serial sections of IPF lung tissues (Figures 7a-e) , fibroblastic cells of FF overexpressing a-SMA (Figure 7b ) and PI3K p110g (Figure 7c) showed positive staining for antibodies against both cyclin-D1 (Figure 7d ) and, as expected, PCNA (Figure 7e ).
DISCUSSION
The molecular mechanisms of IPF pathogenesis are poorly defined and remain a matter of intense discussion and research. In a previous in vitro study, we provided evidence that the PI3K pathway has a major role in both lung fibroblast proliferation and TGF-b-induced differentiation into myofibroblasts, which are hallmarks of IPF. 15 In this research, we evaluated the expression of the class I PI3K p110 isoforms in IPF lung homogenates as well as in tissuederived fibroblast cell lines. Our western blot results show that in IPF lung tissues the overall expression of p110a, p110b and p110d was not significantly different from control tissues whereas p110g was overexpressed. We thus performed immunohistochemical analysis for p110g in IPF tissues and showed that, in addition to the expected interstitial inflammatory cells (eg, lymphocytes, mast cells, and so on), fibroblasts/myofibroblasts exhibited strong nuclear and cytoplasmic immunoreactivity for p110g. Interestingly, bronchiolar basal cells in the abnormal bronchiolar structures of IPF lungs also revealed a pronounced nuclear expression of PI3K p110g. These cells seem to share morphological features with those characterized in a previously published paper 16 indicating that the abnormal proliferation and migration of epithelial basal cells overlying fibroblast foci may have a role in IPF pathological remodeling, leading to bronchiolar colonization/substitution of alveolated parenchyma, leading to lung fibrosis and functional loss. We suggest that the induced overexpression of PI3K p110g in the basal cells of IPF lungs may cause the exaggerated, proliferative character of this cell type in IPF and thus govern the process of bronchiolization in this disease. Moreover, these aberrant bronchiolar basal cells that are often On the other hand, fibroblast proliferation and fibroblastmyofibroblast differentiation as well as the apoptosis-resistant phenotype of myofibroblasts seem to be mediated by enhanced expression and the action of PI3K p110g in fibroblast foci themselves. Interestingly, in this study we observed a proliferative activity of PI3K p110g-positive cells as demonstrated by the expression of PCNA and cyclin D1 markers in the spindle-shaped cells within fibroblastic foci visible in serial sections of IPF lung tissues. This finding is consistent with a previously published paper 13 yet other studies showed a low/very low presence of proliferating cells in fibroblastic foci. 14, 17 On the other hand, increasing evidence suggests that fibroblast proliferation constitutes fundamental ongoing lung injury and activation associated with evolving fibrosis. [18] [19] [20] Moreover, mortality rises in IPF patients who exhibit profusion of fibroblastic foci 21, 22 indicating that the activation of fibroblasts may be a critical regulatory event in the pathogenesis of pulmonary fibrosis. The molecular mechanisms differentiating IPF fibroblasts from their normal counterparts remain unknown. In this research, we isolated fibroblast cell lines from IPF tissues as well as from controls and for the first time we show, in accordance with histological data, significant PI3K p110g overexpression compared with normal cells. This evidence is in line with a recent observation 23 showing that fibroblasts isolated from IPF patients display pathological activation of protein kinase B (Akt, downstream to PI3K). Interestingly, we observed a nuclear localization of p110g, although the substrate for this kinase in the nucleus remains to be determined. Nevertheless, previous studies in a number of cell types showed the existence of an autonomous nuclear polyphosphoinositide metabolism related to cellular proliferation and differentiation. 24, 25 Moreover, p110g translocation to the cell nucleus on serum stimulation was experimentally demonstrated. 26 On the other hand, putative p110g presence in vascular smooth muscle cell (VSMC) nuclei was correlated with the control of VSMC proliferation and in the pathogenesis of vascular proliferative disorders. 27 Furthermore, we decided to investigate the in vitro effects of isoform-selective inhibitors of class I PI3Ks on IPF fibroblast proliferation and fibrogenic activity compared with control cells. As in a previous study on normal fibroblasts, 2 we utilized YM-024, TGX-221 and IC87114 for class IA p110a, p110b and p110d, respectively, and AS-252424 for class IB p110g. Some concerns have retrospectively arisen about the use of this latter as it was very recently shown not to be so specific for p110g, 28 at least in a mouse model, yet no more selective molecule is available, so notwithstanding we targeted experiments with specific siRNAs as the best way to address the role of p110g in fibroblast cell proliferation and fibrogenic activity. Our results show that targeting p110g expression/activity was able to do significantly affect cell proliferation in IPF cultures alone and not in controls. Bearing in mind common features that ourselves and others have previously shown IPF shares with cancer, 29, 30 this finding is particularly interesting considering that in a number of human cancers PI3K p110g has been shown to be involved in controlling cell proliferation. [31] [32] [33] Also a-SMA expression levels were significantly inhibited in IPF fibroblasts by targeting p110g both pharmacologically and genetically.
Our observations are in line with a previously reported in vivo study 34 showing that oral administration of a p110g inhibitor (AS605240) significantly prevented bleomycininduced pulmonary fibrosis in rats also suggesting direct antiproliferative/fibrotic effects on lung fibroblasts, in addition to the stated suppression of inflammatory cell activity.
Taken together, upregulation of PI3K p110g in myofibroblasts and bronchiolar basal cells in IPF may explain the persistence of myofibroblasts and the abnormal proliferation of basal cells in this fatal lung disease. Although further in vivo investigations are needed, our results indicate that PI3K p110g might be considered a new target for treating IPF.
